Hepatitis D medical therapy: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Medical Therapy== | ==Medical Therapy== | ||
Currently there is no effective [[antiviral]] therapy available for treatment of acute or chronic hepatitis D.<ref>{{cite book | last = Fields | first = Bernard | title = Fields virology | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2013 | isbn = 9781451105636 }}</ref> | Currently there is no effective [[antiviral]] therapy available for treatment of acute or chronic hepatitis D.<ref>{{cite book | last = Fields | first = Bernard | title = Fields virology | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2013 | isbn = 9781451105636 }}</ref> | ||
The goal of treatment in hepatitis D is the clearance of the [[HDV]] and of the [[HBV]] helper virus. The complexity of the treatment resides in the need to address | The goal of treatment in hepatitis D is the clearance of the [[HDV]] and of the [[HBV]] helper virus. The complexity of the treatment resides in the need to address both viruses, and in the simplicity of the [[HDV]]. The fact that HDV uses the host cell's enzymes for replication limits the number of targets for therapeutic agents. | ||
Liver transplantation has been helpful for treating fulminant acute and end-stage chronic hepatitis. In one study, the 5-year survival rate of transplant patients for terminal delta cirrhosis was 88% with reappearance of HBsAg only in 9% under long-term anti-HBs prophylaxis.<ref>{{cite book | last = Fields | first = Bernard | title = Fields virology | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2013 | isbn = 9781451105636 }}</ref> | |||
[[Liver transplantation]] has been helpful for treating fulminant acute and end-stage [[chronic hepatitis]]. In one study, the 5-year survival rate of transplant patients for terminal delta cirrhosis was 88% with reappearance of HBsAg only in 9% under long-term anti-HBs prophylaxis.<ref>{{cite book | last = Fields | first = Bernard | title = Fields virology | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2013 | isbn = 9781451105636 }}</ref> | |||
==References== | ==References== | ||
Revision as of 18:51, 6 August 2014
|
Hepatitis D |
|
Diagnosis |
|
Treatment |
|
Hepatitis D medical therapy On the Web |
|
American Roentgen Ray Society Images of Hepatitis D medical therapy |
|
Risk calculators and risk factors for Hepatitis D medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. [2]; João André Alves Silva, M.D. [3] Jolanta Marszalek, M.D. [4]
Overview
Medical Therapy
Currently there is no effective antiviral therapy available for treatment of acute or chronic hepatitis D.[1] The goal of treatment in hepatitis D is the clearance of the HDV and of the HBV helper virus. The complexity of the treatment resides in the need to address both viruses, and in the simplicity of the HDV. The fact that HDV uses the host cell's enzymes for replication limits the number of targets for therapeutic agents.
Liver transplantation has been helpful for treating fulminant acute and end-stage chronic hepatitis. In one study, the 5-year survival rate of transplant patients for terminal delta cirrhosis was 88% with reappearance of HBsAg only in 9% under long-term anti-HBs prophylaxis.[2]
References
- ↑ Fields, Bernard (2013). Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 9781451105636.
- ↑ Fields, Bernard (2013). Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 9781451105636.